SGP

SpyGlass Pharma Inc

Feb 06 • 04:00PM ET

26.40

+10.40 65.00 %

Healthcare • Biotechnology • USA • NASD

Today, 1:01 PMIPO debut sparks 59.72% surge on first day of trading.

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	31.91M	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-
Book/sh	-1.90	P/C	-	EPS next 5Y	-	ROE	-	52W High	- -	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	- -	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	12.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	-	SMA20	0.00%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	0.00%	Rel Volume	-	Prev Close	16.00
Employees	-	LT Debt/Eq	0.29	Earnings	-	SMA200	0.00%	Avg Volume	-	Price	26.40
IPO	Feb 06, 2026	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	1,191,668	Change	65.00%

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGP

SpyGlass Pharma Inc

Upgrade your FINVIZ experience